EVAX logoEVAX
Evaxion Biotech

3,419
Loading...
Loading...
News
all
press releases
Evaxion Biotech A/S (NASDAQ:EVAX) Stock Rating Upgraded by LADENBURG THALM/SH SH
LADENBURG THALM/SH SH upgraded shares of Evaxion Biotech A/S (NASDAQ:EVAX - Free Report) from a neutral rating to a buy rating in a report published on Tuesday, Marketbeat.com reports. The firm...
Ticker Report·1y ago
News Placeholder
More News
News Placeholder
Q4 2023 Evaxion Biotech A/S Earnings Call (Danish) Transcript
Related Stocks: NAS:EVAX...
GuruFocus·1y ago
News Placeholder
Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection
Evaxion and its collaborator tested Evaxion-designed vaccine antigens against Staphylococcus aureus in a clinically relevant animal model of surgical site infectionsThe vaccine antigens significantly...
Globe Newswire·1y ago
News Placeholder
Evaxion Biotech Announces Upcoming Annual Meeting
Evaxion Biotech A/S Adr (EVAX) has released an update. Evaxion Biotech A/S has announced its annual general meeting scheduled for April 16, 2024, e...
TipRanks Financial Blog·1y ago
News Placeholder
Evaxion Announces Business Update and Full Year 2023 Financial Results
Precision vaccine project initiated with the ambition to obtain Preclinical Proof-of-Concept by H2 2024. The novel concept entails AI-identification of a new class of cancer vaccine targets, named...
Globe Newswire·1y ago
News Placeholder
Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology Platform
The proprietary AI-Immunology platform brings the potential for a new era in vaccine discovery, design and development using advanced AI and machine learning technologiesAI-Immunology outcompetes...
Globe Newswire·1y ago
News Placeholder
Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations
COPENHAGEN, Denmark, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ( Evaxion or the Company ), a clinical-stage TechBio company specializing in developing AI-Immunology...
Globe Newswire·2y ago
News Placeholder
Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD
COPENHAGEN, Denmark, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology...
Globe Newswire·2y ago
News Placeholder
Evaxion Biotech A/S Expected to Post FY2023 Earnings of ($6.90) Per Share (NASDAQ:EVAX)
Evaxion Biotech A/S (NASDAQ:EVAX Free Report) Equities researchers at HC Wainwright issued their FY2023 earnings per share estimates for shares of Evaxion Biotech A/S in a note issued...
Zolmax·2y ago
News Placeholder
Evaxion Regains Compliance with Nasdaq Minimum Bid Price Requirement
COPENHAGEN, Denmark, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ( Evaxion or the Company ), a clinical-stage TechBio company specializing in developing AI-Immunology...
Globe Newswire·2y ago

Latest EVAX News

View

Advertisement. Remove ads.

Advertisement. Remove ads.